Mucopolysaccharidosis I
FDA Places Clinical Holds on Regenxbio’s RGX-111 and RGX-121 Gene Therapy Trials After Brain Tumor in Patient
FDA clinical hold; Regenxbio; RGX-111; RGX-121; brain tumor; gene therapy; MPS I; MPS II; AAV vector
Actionable Insights Powered by AI
FDA clinical hold; Regenxbio; RGX-111; RGX-121; brain tumor; gene therapy; MPS I; MPS II; AAV vector